Background {#Sec1}
==========

Age-related macular degeneration (AMD) is a progressive chronic disease of the central retina (the macula) and will result primarily in loss of central vision. It has become the leading cause of adult blindness in industrialized countries \[[@CR1]\]. The incidence is expected to at least double by 2020 \[[@CR2]\]. The Global Burden of Disease Study 2010 reported an exponential increase of 160% in vision-related years lived with disability due to AMD, highlighting the overwhelming burden to society \[[@CR3]\]. A systematic review also revealed that, in 2010, 2.1 million people were blind and 6.0million people were visually impaired due to macular diseases, excluding those caused by diabetic maculopathy \[[@CR4]\]. Its prevalence increased from 1990 to 2010 with the highest increase in high-income regions and among the older population (≥50 years of age). The prevalence is comparable between Asians and whites \[[@CR5]\], but lower in blacks \[[@CR6]\]. However, Asians are more likely to have less-common AMD variants (polypoidal choroidal vasculopathy, PCV) \[[@CR7], [@CR8]\].

Clinically, AMD is classified into dry (atrophic) or wet (neovascular or exudative, which accounts for more than 80% of cases with severe visual loss or legal blindness \[[@CR9]\]). Established therapies for wet AMD include intravitreous injection of a vascular endothelial growth factor (VEGF) inhibitor, possibly thermal laser photocoagulation, photodynamic therapy (PDT), and supplementation with zinc and antioxidant vitamins. PDT is an alternative for patients who cannot be treated with an intravitreal VEGF inhibitor and for patients with chronic exudative lesions who have preserved vision in one eye and are unlikely to achieve reading vision in the second eye. Transpupillary thermotherapy and triamcinolone acetonide are also used for wet AMD, but recurrence rates of both therapies are relatively high. According to the guidelines from American Academy of Ophthalmology (AAO) and the European Society of Retina Specialists (EURETINA), VEGF inhibitors (e.g., aflibercept, bevacizumab, and ranibizumab) are most effective to manage neovascular AMD and are considered first-line of treatment \[[@CR2], [@CR10]\].

VEGF (a potent mitogen and vascular permeability factor) plays a pivotal role in neovascularization by increasing vascular permeability, enhancing the inflammatory response and inducing angiogenesis \[[@CR11]\]. Inhibiting VEGF can limit the progression of wet AMD and stabilize, or reverse visual loss \[[@CR12]\]. Between 2004 and 2006, three anti-VEGF drugs (Pegaptanib, ranibizumab, and bevacizumab) with different sites of action, formulations, binding affinities, and biologic activities were introduced for the treatment of wet AMD. In November 2011, aflibercept, which binds to all VEGF-A and VEGF-B isoforms as well as to the highly related placental growth factor (PIGF) was approved by the US Food and Drug Adminstration. Similar to aflibercept, conbercept (KH902), a recombinant fusion protein with high affinity to all VEGF isoforms and PIGF \[[@CR13]\], was developed and approved in China for the treatment of wet AMD in December 2013. Several randomized trials investigating the use of conbercept concluded that it was effective and safe in the treatment of wet AMD. Nevertheless, evidence has not been systematically assessed. To understand and interpret available evidence, we conducted a systematic review to evaluate the efficacy and safety of conbercept in patients with wet AMD.

Methods {#Sec2}
=======

We followed the standard set by Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) in this systematic review (Additional file [1](#MOESM1){ref-type="media"}: Table S1). The study was registered in PROSPERO International Prospective Register of Systematic Review (PROSPERO 2017: CRD42017071144).

Literature searching {#Sec3}
--------------------

Pubmed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) published in Cochran Library were searched using the search strategies detailed in Additional file [1](#MOESM1){ref-type="media"}: Table S2, from their earliest records to June 2017. [Clinicaltrials.gov](http://clinicaltrials.gov) was searched with the terms "age-related macular degeneration" and "conbercept". The China National Knowledge Infrastructure(CNKI), VIP database, and Wanfang database were also searched with Chinese terms.

Eligibility criteria {#Sec4}
--------------------

All included studies met the following criteria: (1) randomized controlled studies (RCTs); (2) participants with wet age-related macular degeneration aged more than 50 years old; (3) the intervention was conbercept irrespective of dosage and schedule; (4) the comparisons included conservative treatment, ranibizumab, transpupillary thermotherapy, and triamcinolone acetonide; (5) studies included at least one of the following outcomes: the primary outcome was the mean change in best-corrected visual acuity (BCVA, which was measured by the logarithmic visual acuity chart) from baseline to the third month after the first treatment; secondary outcomes included the mean change in central retinal thickness (CRT, which was measured by optical coherence tomography) from baseline to the last visit, the mean change in plasma level of VEGF from baseline to the last visit, and the incidence of adverse events (AEs); (6) publication written in English or Chinese. We excluded the patients with glaucoma, cataracts, or retinopathy caused by diabetes or hypertension and studies without available raw data.

Study selection and data extraction {#Sec5}
-----------------------------------

Two investigators independently screened the titles and abstracts of the articles identified by literature searching (Additional file [1](#MOESM1){ref-type="media"}: Table S2 shows the searching strategy), and assessed the studies using predetermined inclusion criteria. The full texts of all potentially relevant articles were retrieved for detailed review. Any disagreement in the process of selection was resolved by discussion. Two authors independently extracted following data from included articles: (1) authors; (2) year of publication; (3) country or region where the study was conducted; (4) study design and use of control; (5) number of participants randomized into each group; (6) gender, age, and disease duration of participants; (7) treatment regimens (dose and schedule); (8) outcomes of each study and their definitions; (9) numerical data for outcomes assessment; (10) sources of funding.

Risk of Bias assessment {#Sec6}
-----------------------

Two authors independently assessed the bias risk of each included study using the checklist developed by Cochrane Collaboration \[[@CR14], [@CR15]\]. Any disagreements about the risk of bias was resolved by discussion. The items included random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other bias. We categorized the judgments as low, high or unclear risk of bias and created plots of bias risk assessment in Review Manager Software (RevMan 5.3).

Statistical synthesis {#Sec7}
---------------------

We calculated a kappa statistic for measuring the agreement level between two authors regarding to the decisions made on study selection. The value of kappa (*K*) 0.40--0.59 was considered fair agreement, 0.60--0.74 as good and 0.75 or more as excellent \[[@CR16]\].

If more than one study reported the same outcome, a pairwise meta-analysis was conducted. We analyzed RCTs using risk ratios (*RRs*) for the incidence of AEs and mean differences (*MDs*) for BCVA, CRT, and VEGF level, with corresponding 95% confidence intervals (*CIs*) to compare differences between conbercept and control groups. We pooled *RRs* with the Mantel-Haenszel method, and *MDs* with the inverse variance method using RevMan 5.3, respectively. Statistical heterogeneity among studies was examined by the Chi-square test and quantified by the *I*^*2*^ statistic \[[@CR14]\]. We applied a fixed-effects model to synthesize data when heterogeneity was not significant (*P\>*0.1 and *I*^*2*^\<50%). When heterogeneity was significant (*P* ≤ 0.1 and *I*^*2*^ ≥ 50%) and could not be explained by subgroup analyses or in terms of clinical or methodological features of the trials, a random-effects model was used. We explored sources of heterogeneity based on the following subgroup analyses: type of control groups (e.g. conservative treatment, triamcinolone acetonide, transpupillary thermotherapy, or ranibizumab). We carried out sensitivity analyses by using alternative pooling methods (Peto vs. Mantel-Haenszel method), and statistical models regarding to heterogeneity (random-effects vs. fixed-effect).

Results {#Sec8}
=======

Search results and characteristics of included studies {#Sec9}
------------------------------------------------------

A total of 780 citations were obtained from the literature search and the selection process is shown in Fig. [1](#Fig1){ref-type="fig"}. Eighteen RCTs (1285 participants) \[[@CR17]--[@CR34]\] were included in this systematic review. Agreement on study selection between two reviewers was excellent (*K* = 0.83). All the RCTs were single-center studies conducted in China. As shown in Table [1](#Tab1){ref-type="table"}, the comparisons were conservative treatment (3 RCTs \[[@CR17]--[@CR19]\], 232 participants), ranibizumab (6 RCTs \[[@CR20]--[@CR25]\], 395 participants), transpupillary thermotherapy (4 RCTs \[[@CR26]--[@CR29]\], 326 participants), and triamcinolone acetonide (5 RCTs \[[@CR30]--[@CR34]\], 332 participants). The follow-up time ranged from 1 to 12 months after the first treatment, except one study \[[@CR18]\] without reporting this information.Fig. 1Flow diagram of study selection process for this systematic reviewTable 1Characteristic of included studiesStudy IDStudy designParticipants*N*Intervention group (*N*)Comparison group (*N*)OutcomesFollow-up time after the first treatment (months)Li YY, 2017 \[[@CR17]\]RCTwet AMD54Conbercept (27)Conservative treatment (27)②④6Mei HY, 2017 \[[@CR18]\]RCTwet AMD66Conbercept (33)Conservative treatment (33)②NASong W, 2016 \[[@CR19]\]RCTwet AMD112Conbercept (56)Conservative treatment (56)②④6Liu ZN, 2016 \[[@CR20]\]RCTwet AMD40Conbercept (20)Ranibizumab (20)②12Zhang HX, 2016 \[[@CR21]\]RCTwet AMD50Conbercept (25)Ranibizumab (25)②③④1Liu R, 2015 \[[@CR22]\]RCTwet AMD60Conbercept (30)Ranibizumab (30)②③3Wang NF, 2017 \[[@CR23]\]RCTwet AMD76Conbercept (38)Ranibizumab (38)①②3Lyu P, 2016 \[[@CR24]\]RCTwet AMD84Conbercept (42)Ranibizumab (42)①②④3Zheng MW, 2017 \[[@CR25]\]RCTwet AMD85Conbercept (42)Ranibizumab (43)①②3Wang XX, 2015 \[[@CR26]\]RCTwet AMD60Conbercept (30)Transpupillary thermotherapy (30)②6Qin MM, 2016 \[[@CR27]\]RCTwet AMD82Conbercept (41)Transpupillary thermotherapy (41)②3Li L, 2017 \[[@CR28]\]RCTwet AMD86Conbercept (43)Transpupillary thermotherapy (43)②④6Zhang X, 2015 \[[@CR29]\]RCTwet AMD98Conbercept (49)Transpupillary thermotherapy (49)②6Zhu Y, 2017 \[[@CR30]\]RCTwet AMD50Conbercept (25)Triamcinolone acetonide (25)①②④3He XT, 2015 \[[@CR31]\]RCTwet AMD60Conbercept (30)Triamcinolone acetonide (30)①②④3Han X, 2017 \[[@CR32]\]RCTwet AMD70Conbercept (35)Triamcinolone acetonide (35)①②④3Pan XL, 2017 \[[@CR33]\]RCTwet AMD76Conbercept (38, 42eyes)Triamcinolone acetonide (38, 38eyes)②12Yue JL, 2017 \[[@CR34]\]RCTwet AMD76Conbercept (38)Triamcinolone acetonide (38)②12*RCT* randomized controlled trials, *AMD* age-related macular degeneration, *N* number of participants, *NA* not available; ① the mean change in best-corrected visual acuity from baseline to the third month after the first treatment; ② the mean change in central retinal thickness from baseline to the last visit; ③ the mean change in plasma level of VEGF from baseline to the last visit; ④ adverse events

As shown in Table [2](#Tab2){ref-type="table"}, all participants were aged 51--87 years old with disease duration of 7 days to 10 years (10 studies \[[@CR17], [@CR19], [@CR23]--[@CR26], [@CR28]--[@CR31]\] did not report the disease duration). The reported dose of conbercept ranged from 0.5 to 1.5 mg, except 2 studies \[[@CR21], [@CR30]\] which failed to report dosing information.Table 2Therapeutic regimen and characteristic of included participantsStudy IDTherapeutic regimen of intervention groupTherapeutic regimen of comparison groupGender(male/female): intervention group vs comparison groupAge(years): intervention group vs comparison groupCourse of disease: intervention group vs comparison groupLi YY, 2017 \[[@CR17]\]Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.Conservative treatment16/11 vs 14/1376.8 ± 12.6(58--85) vs 77.6 ± 11.9(59--83)NAMei HY, 2017 \[[@CR18]\]Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.Conservative treatment17/16 vs 16/1769.4 ± 4.3(63--72) vs 69.5 ± 4.1(63--71)3.1 ± 0.5y(2-4y) vs 3.2 ± 0.6y(2-5y)Song W, 2016 \[[@CR19]\]Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.Conservative treatment30/26 vs 29/2762.36 ± 6.56(53--81) vs 63.29 ± 6.45(54--82)NALiu ZN, 2016 \[[@CR20]\]Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.Ranibizumab, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.11/9 vs 12/865.41 ± 6.37(57--86) vs 65.36 ± 6.74(56--85)3.81 ± 1.10y(6 m-10y) vs 3.88 ± 1.20y(7 m-11y)Zhang HX, 2016 \[[@CR21]\]Conbercept, NARanibizumab, NA12/13 vs 13/1268.79 ± 7.21(54--81) vs 69.03 ± 7.01(53--82)6.13 ± 4.27 m(7d-14 m) vs 6.25 ± 4.45 m(3d-15 m)Liu R, 2015 \[[@CR22]\]Conbercept, 1.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.Ranibizumab, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.NA65.5 ± 8.1(53--83) vs 65.2 ± 8.3(54--81)18.8 ± 4.1 m(8-31 m) vs 19.0 ± 4.2 m (9-32 m)Wang NF, 2017 \[[@CR23]\]Conbercept, 0.5 mg, intravitreal injectionRanibizumab, 0.5 mg, intravitreal injection19/19 vs 20/1862.89 ± 5.46(51--75) vs 62.85 ± 5.41(52--74)NALyu P, 2016 \[[@CR24]\]Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.Ranibizumab, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.22/20 vs 21/2162.7 ± 5.3(51--73) vs 62.1 ± 4.9(49--70)NAZheng MW, 2017 \[[@CR25]\]Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.Ranibizumab, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.25/17 vs 26/1765.34 ± 2.29(61--72) vs 65.13 ± 2.27(61--74)NAWang XX, 2015 \[[@CR26]\]Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.Transpupillary thermotherapy, course of treatment: 3 months17/13 vs 16/1470.4 ± 8.4 vs 69.7 ± 8.1NAQin MM, 2016 \[[@CR27]\]Conbercept, 1.0 mg, intravitreal injection, once a month, continuous treatment for 3 months.Transpupillary thermotherapy, course of treatment: 3 months20/21 vs 22/1965.8 ± 7.5(54--81) vs 64.9 ± 7.7(51--79)5.7 ± 4.4y(9 m-25y) vs 4.7 ± 3.2y(11 m-21y)Li L, 2017 \[[@CR28]\]Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.Transpupillary thermotherapy, course of treatment: 3 monthsNA62.28 ± 3.21(52--82) vs 63.12 ± 4.36(53--83)NAZhang X, 2015 \[[@CR29]\]Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.Transpupillary thermotherapy, course of treatment: 3 monthsNA64.19 ± 4.31(54--85) vs 65.43 ± 5.76(55--86)NAZhu Y, 2017 \[[@CR30]\]Conbercept, NATriamcinolone acetonide, 0.1 ml, intravitreal injection.NANANAHe XT, 2015 \[[@CR31]\]Conbercept, 1.0 mg, intravitreal injection.Triamcinolone acetonide, 0.1 ml, intravitreal injection.14/16 vs 13/1761.52 ± 6.8(57--72) vs 61.30 ± 6.2(55--70)NAHan X, 2017 \[[@CR32]\]Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months.Triamcinolone acetonide, 0.1 ml, intravitreal injection, once a month, continuous treatment for 3 months.16/19 vs 14/2167.54 ± 4.45(55--83) vs 68.12 ± 4.66(54--87)3.75 ± 0.64y(0.5-10y) vs 3.94 ± 0.71y(0.5-12y)Pan XL, 2017 \[[@CR33]\]Conbercept, 1.0 mg, intravitreal injectionTriamcinolone acetonide, 0.1 ml, intravitreal injection.20/18 vs 22/1671.62 ± 5.27(63--85) vs 71.59 ± 5.11(62--83)15.83 m ± 5.25 m(5-25 m) vs 15.65 m ± 5.34 m(7-29 m)Yue JL, 2017 \[[@CR34]\]Conbercept, 0.5 mg, intravitreal injectionTriamcinolone acetonide, 0.1 ml, intravitreal injection.21/17 vs 22/1669.78 ± 7.52(61--82) vs 69.27 ± 8.36(60--81)45.62 ± 14.79 m(5-126 m) vs 46.15 ± 14.34 m(7-123 m)*NA* not available, *d* day, *m* month, *y* year

Risk of Bias {#Sec10}
------------

As shown in Fig. [2](#Fig2){ref-type="fig"}, the random sequences of 11 studies \[[@CR19], [@CR21], [@CR23], [@CR24], [@CR28]--[@CR31], [@CR33], [@CR34]\] were generated by a random number table or simulation, while all the studies failed to describe the method of allocation concealment. Therefore, the risk of selection bias related to allocation concealment was unable to be assessed. The risk of performance bias of all studies was uncertain, as the blinding method was not reported. All studies had low risk of attrition bias, as there was no loss to follow-up. No studies contained information related to registration information nor had protocols available, so it was unknown whether all the pre-designed outcomes in these studies had been reported. Since none of the studies were reported being supported by pharmaceutical industry funding, the bias caused by conflict of interest was low. Due to the limited number of the included studies for the same outcome, publication bias investigation was not performed.Fig. 2Risk of bias summary

Best-corrected visual acuity (BCVA) {#Sec11}
-----------------------------------

The mean change in BCVA from baseline to the third month after the first treatment was reported in 6 studies \[[@CR23]--[@CR25], [@CR30]--[@CR32]\] (435 participants). Subgroup analyses were performed and stratified by control group selection (Fig. [3](#Fig3){ref-type="fig"}). The heterogeneity of each subgroup was not statistically significant (*I*^*2*^\<50%, *P*\>0.1), so the *MD*s of the mean changes of BCVA were pooled with a fixed-effects model. The difference between the pooled results of the two subgroups was significant (*P* \< 0.00001). Compared to triamcinolone acetonide, conbercept significantly improved the BCVA in the third month after the first treatment \[*MD* = 0.11, 95%*CI* (0.08, 0.15)\]. While the mean change in BCVA from baseline in conbercept group was similar to that in ranibizumab group \[*MD* = 0.00, 95% *CI* (− 0.03, 0.04)\].Fig. 3The forest plot of best-corrected visual acuity

Central retinal thickness (CRT) {#Sec12}
-------------------------------

The mean change in CRT from baseline to the last visit was reported in all 18 studies \[[@CR17]--[@CR34]\] (1285 participants). Subgroup analyses were performed and stratified by control group selection (Fig. [4](#Fig4){ref-type="fig"}). The *MD*s of the mean changes of CRT were pooled with a fixed-effects model because the heterogeneity of each subgroup was not statistically significant (*I*^*2*^\<50%, *P*\>0.1). There were significant differences among the pooled results of the four subgroups (*P* \< 0.00001). Compared with the other four therapies (conservative treatment, ranibizumab, transpupillary thermotherapy, triamcinolone acetonide), conbercept significantly reduced the CRT at the last visit \[*MD* = − 49.51, 95% *CI* (− 67.45, − 31.58); *MD* = − 9.96, 95% *CI* (− 17.61, − 2.32); *MD* = − 60.51, 95% *CI* (− 92.14, − 28.89); *MD* = − 79.17, 95% *CI* (− 96.34, − 61.99), respectively\].Fig. 4The forest plot of central retinal thickness

Plasma level of VEGF(ng/L) {#Sec13}
--------------------------

Two studies \[[@CR21], [@CR22]\] (110 participants) reported the plasma level of VEGF. According to Fig. [5](#Fig5){ref-type="fig"}, the heterogeneity was not statistically significant (*I*^*2*^ = 0%, *P* = 0.62). The pooled results with a fixed-effects model indicated that conbercept significantly lowered the plasma level of VEGF \[*MD* = − 15.86, 95% *CI* (− 23.17, − 8.55)\] compared to ranibizumab.Fig. 5The forest plot of plasma level of vascular endothelial growth factor (VEGF)

Adverse events (AEs) {#Sec14}
--------------------

Eight studies \[[@CR17], [@CR19], [@CR21], [@CR24], [@CR28], [@CR30]--[@CR32]\] (566 participants) reported the incidence of any AEs. Due to the significant heterogeneity in conbercept vs. conservative treatment subgroup (*I*^*2*^ = 75%, *P* = 0.05), the RRs were pooled with a random-effects model (Fig. [6](#Fig6){ref-type="fig"}). The incidence of AEs in the conbercept group was similar to the conservative treatment \[*RR* = 8.81, 95% *CI* (0.20, 388.62)\], ranibizumab \[*RR* = 1.25, 95% *CI* (0.38, 4.12)\] \[[@CR21]\], and transpupillary thermotherapy groups \[*RR* = 5.00, 95% *CI* (0.25, 101.81)\] \[[@CR28]\], but significantly lower than triamcinolone acetonide group \[*RR* = 0.25, 95% *CI* (0.09, 0.72)\]. None of the studies reported serious AEs, and the most common AEs were increased IOP and ophthalmecchymosis. The incidences of increased IOP (Fig. [7](#Fig7){ref-type="fig"}) and ophthalmecchymosis (Fig. [8](#Fig8){ref-type="fig"}) in the conbercept group were similar to ranibizumab \[*RR* = 0.20, 95% *CI* (0.01, 3.97); *RR* = 1.50, 95% *CI* (0.27, 8.22), respectively\] \[[@CR21]\], transpupillary thermotherapy \[*RR* = 3.00, 95% *CI* (0.13, 71.65); *RR* = 3.00, 95% *CI* (0.13, 71.65), respectively\] \[[@CR28]\], and triamcinolone acetonide \[*RR* = 0.50, 95% *CI* (0.13, 1.94); *RR* = 3.00, 95% *CI* (0.13, 71.22) \[[@CR32]\], respectively\] groups, but were significantly higher than conservative treatment group \[*RR* = 14.00, 95% *CI* (1.88, 104.25); *RR* = 20.00, 95% *CI* (2.74, 145.96), respectively\].Fig. 6The forest plot of the incidence of adverse eventsFig. 7The forest plot of the incidence of increased intraocular pressureFig. 8The forest plot of the incidence of ophthalmecchymosis

Sensitivity analysis {#Sec15}
--------------------

The sensitivity analyses were performed by pooling methods and statistical models regarding to test heterogeneity, and the results (BCVA, CRT, Plasma level of VEGF, and AEs) were robust.

Discussion {#Sec16}
==========

This systematic review summarized the evidence of efficacy and safety of conbercept in patients with wet AMD. Our study suggests that the use of conbercept improves the BCVA compared to triamcinolone acetonide, and reduce the CRT compared to the other four therapies (conservative treatment, ranibizumab, transpupillary thermotherapy, and triamcinolone acetonide). The safety profile of conbercept is superior to triamcinolone acetonide, but similar to other controls. As to the anti-VEGF agents, conbercept seems to be more effective than ranibizumab in lowering the plasma level of VEGF.

Although the doses of conbercept reported in the RCTs ranged from 0.5 to 1.5 mg, a double-blinded, multicenter, controlled-dose RCT concluded that the mean improvement in BCVA, the mean reduction in CRT, and the incidences of AEs were of no significant difference between 0.5 and 2.0 mg conbercept dosing groups in treating neovascular AMD patients \[[@CR35]\]. Accordingly, we supposed that different doses of conbercept did not cause the clinical heterogeneity.

The current evidence demonstrates the advantages of conbercept over the non-anti-VEGF agent controls; however, these controls were rarely used for treatment of wet AMD due to the relatively high recurrence rate. This systematic review indicated comparable efficacy in improving BCVA between conbercept and ranibizumab, which was consistent with a retrospective case-controlled study including 180 patients \[[@CR36]\]. There were also many studies \[[@CR20], [@CR22], [@CR27], [@CR33], [@CR34], [@CR37]\] reporting naked vision as an outcome rather than BCVA. Naked vision was too susceptible to many other factors to be used as the outcome for wet AMD. Therefore we recommend BCVA should be set as the uniform outcome for measuring visual acuity in the future studies.

Our study also found that, compared with ranibizumab, conbercept significantly reduced the CRT, which was slightly inconsistent with Cui et al. \[[@CR36]\]. The stronger effect of conbercept on reducing CRT might be on account of different mechanisms of action of the two anti-VEGF agents: ranibizumab, a fully humanized monoclonal antibody fragment, functions by blocking the receptor binding domains of all VEGF-A isoforms \[[@CR38]\]; while conbercept, a novel recombinant fusion protein, binds to not only VEGF-A but also VEGF-B and PIGF \[[@CR35]\]. Cui et al \[[@CR36]\] also found a slightly more CRT improvement in the conbercept group than that in the ranibizumab group, but the difference was not statistically significant, which might be attributed to the influence of confounding factors and small sample size.

A prospective, interventional case series \[[@CR39]\] including 28 patients concluded that conbercept significantly decreased serum VEGF level at 1 day and 1 week after injection, while ranibizumab had no significant effect on serum VEGF concentration, which was consistent with our study. The reduction in serum VEGF may affect conbercept's systemic safety profile, but the result of meta-analysis did not show any significant difference between conbercept and ranibizumab, which was consistent with Cui et al \[[@CR36]\]. Due to the small sample size and short follow-up period of included RCT, the safety of conbercept needs to be further evaluated by long-term, larger sample size study.

On the other hand, a cost-effectiveness analysis \[[@CR40]\] based on a Markov model concluded that conbercept was a cost-effective alternative for the treatment of wet AMD in China, compared with ranibizumab. Considering the limitation of model and paucity of studies about life quality of patients with wet AMD, the pharmacoeconomic research in real-world population should be conducted in the future.

The limitations of this study must be acknowledged as follow: 1) Included RCT were all conducted in Chinese population because conbercept is only approved in China, which limited the representativeness of sample and generalization of the conclusions. Hence the efficacy and safety of conbercept needed to be evaluated in other racial population. 2) Included RCTs with small sample size and short-term follow-up phase were not sensitive enough to find rare AEs, so the safety of conbercept should be further-assessed in larger samples and longer follow-up. 3) The methodological quality of the primary studies was poor, especially without descriptions about allocation concealment and blinding methods as well as registration information. In addition, the overall small size of all studies contributing to any one treatment effect limited the power of statistical tests in meta-analysis. Therefore, prospective, multicenter, RCTs with larger samples and better methodological design are urgently needed in this therapeutic area.

Conclusion {#Sec17}
==========

In conclusion, current evidence suggests that conbercept is a promising option for the treatment of wet AMD. Due to the limitations of included studies, further studies (RCTs with larger sample and better methodological design) are warranted to compare the efficacy, long-term safety and cost-effectiveness between conbercept and other anti-VEGF agents (e.g. ranibizumab) in different populations. And researchers should increase focus on patient-reported outcomes (eg. quality of life) in the further research.
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